Pre-made Sofituzumab Vedotin benchmark antibody (Whole mAb ADC, anti-MUC16 therapeutic antibody, Anti-CA125 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-994
Pre-made Sofituzumab Vedotin benchmark antibody (Whole mAb ADC, anti-MUC16 therapeutic antibody, Anti-CA125 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sofituzumab vedotin (INN;[1] development code DMUC5754A) is a monoclonal antibody designed for the treatment of ovarian cancer.[2]
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-INN-994-1mg | 1mg | 4635 | ||
GMP-Bios-INN-994-10mg | 10mg | Inquiry | ||
GMP-Bios-INN-994-100mg | 100mg | Inquiry | ||
GMP-Bios-INN-994-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Sofituzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Muc16 Antibody: Anti-CA125 therapeutic antibody Drug Conjugate |
INN Name | Sofituzumab Vedotin |
Target | MUC16 |
Format | Whole mAb ADC |
Derivation | Humanized |
Species Reactivity | human |
CH1 Isotype | IgG1 - kappa |
VD LC | IgG1 - kappa |
Highest_Clin_Trial (Jan '20) | |
Est. Status | |
100% SI Structure | |
99% SI Structure | |
95-98% SI Structure | |
Year Proposed | |
Year Recommended | |
Companies | Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland) |
Conditions Approved | |
Conditions Active | |
Conditions Discontinued | |
Development Tech | 0 |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<